http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019261668-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f704b79aad33812dcfaed35097af8513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf5b831afcf190a8ae4d29cfbbe17a08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c9109887d9b2c410cddcf93e23317d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dca113e5a1ba3632a139e3aee53d4094 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-1598 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-712 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-7144 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-7044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-306 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-708 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-1578 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-1592 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-1642 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-161 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-105 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-155 |
| filingDate | 2019-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3afa182b89bc688f4c2e1130ea4f036a |
| publicationDate | 2019-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2019261668-A1 |
| titleOfInvention | Treatment and Prevention of Bone and Joint Disorders |
| abstract | The invention encompasses compositions and methods for effectively treating and/or preventing the development and/or progression of osteoporosis and related disorders such as osteoarthritis and rheumatoid arthritis, and for promoting overall bone and joint health. This is accomplished by addressing multiple key mechanisms that lead to such disorders. The invention includes compositions comprising a combination of agents having biological activities that effectively suppress, regulate or interfere with the various key biochemical processes and mechanisms that increase the risk for development and/or progression of osteoporosis. The present compositions and methods simultaneously promote bone formation and reduce bone resorption by (a) stimulating osteoblast formation and osteogenesis; (b) suppressing adipocyte differentiation; (c) inhibiting osteoclast formation; and (d) increasing apoptosis of osteoclasts. The inventive compositions used for administration to human and other mammalian subjects having or at risk for development of osteoporosis comprise (1) at least one agent capable of modulating expression and/or activity of one or more of peroxisome activated protein receptor gamma (PPAR-γ), CAAT/enhancer binding protein-α (C/EBPα) and Sterol Regulatory Element-Binding Protein (SREBP-1); (2) at least one agent that activates expression and/or activity of one or more of the osteogenic transcription factors (Runx2/Cbfα1, Dlx5, Osterix, Msx2); (3) at least one agent that activates expression and/or activity of one or more of bone morphogenetic proteins (BMPs: BMP 2 and 4), alkaline phosphatase (ALP), and osteocalcin; (4) at least one agent capable of activating Wnt/β-catenin signaling pathway; (5) at least one agent that inhibits the activity of pro-oxidants including reactive nitrogen species and reactive oxygen species (ROS); (6) at least one agent that suppresses one or more of inflammatory mediators including interleukins IL-1α, IL-1β, IL-6, NF-κB, TNF-α, matrix metalloproteinases (MMPs) and prostaglandin E2 (PGE2); and (7) at least one agent that induces the expression of and/or activates one or more of adenosine monophosphate-activated protein kinase (AMPK), sirtuin (SIRT1) and adiponectin (AP). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022180119-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023033106-A1 |
| priorityDate | 2017-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2080.